- Home
- OGI vs MDWD Comparison
OGI vs MDWD Comparison
Compare OGI & MDWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- MDWD
- Stock Information
- Founded
- OGI 2013
- MDWD 2000
- Country
- OGI Canada
- MDWD Israel
- Employees
- OGI N/A
- MDWD N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- MDWD Medicinal Chemicals and Botanical Products
- Sector
- OGI Health Care
- MDWD Health Care
- Exchange
- OGI Nasdaq
- MDWD Nasdaq
- Market Cap
- OGI 180.7M
- MDWD 208.2M
- IPO Year
- OGI N/A
- MDWD 2014
- Fundamental
- Price
- OGI $1.45
- MDWD $19.74
- Analyst Decision
- OGI
- MDWD Strong Buy
- Analyst Count
- OGI 0
- MDWD 2
- Target Price
- OGI N/A
- MDWD $35.00
- AVG Volume (30 Days)
- OGI 578.1K
- MDWD 47.9K
- Earning Date
- OGI 08-12-2025
- MDWD 08-13-2025
- Dividend Yield
- OGI N/A
- MDWD N/A
- EPS Growth
- OGI N/A
- MDWD N/A
- EPS
- OGI 0.10
- MDWD N/A
- Revenue
- OGI $135,031,829.00
- MDWD $19,213,000.00
- Revenue This Year
- OGI $50.30
- MDWD $20.80
- Revenue Next Year
- OGI $16.01
- MDWD $26.92
- P/E Ratio
- OGI $14.03
- MDWD N/A
- Revenue Growth
- OGI 20.49
- MDWD N/A
- 52 Week Low
- OGI $0.85
- MDWD $14.14
- 52 Week High
- OGI $2.08
- MDWD $22.51
- Technical
- Relative Strength Index (RSI)
- OGI 58.57
- MDWD 50.69
- Support Level
- OGI $1.36
- MDWD $19.07
- Resistance Level
- OGI $1.44
- MDWD $19.55
- Average True Range (ATR)
- OGI 0.06
- MDWD 0.56
- MACD
- OGI 0.00
- MDWD -0.03
- Stochastic Oscillator
- OGI 97.50
- MDWD 88.89
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About MDWD MediWound Ltd.
MediWound Ltd is an integrated biopharmaceutical company focused on developing, manufacturing, and commercializing novel therapeutic products to address unmet medical needs in the fields of severe burns, chronic and other hard-to-heal wounds, connective tissue disorders, and other indications. Its first biopharmaceutical product, NexoBrid is an FDA-approved orphan biologic for eschar removal in severe burns that can replace surgical interventions and minimize associated costs and complications. Its other product candidates in different stages of the pipeline include EscharEx for debridement of chronic wounds, and MW005 for the treatment of non-melanoma skin cancer. The company derives a majority of its revenue from the United States and the rest from the EU and other international markets.